Investment Landscape: Sirtuin Therapeutics for Neurodegeneration
Executive Summary
flowchart TD
investment_sirtuin_therapeutic["Investment Landscape: Sirtuin Therapeutics for N"]
style investment_sirtuin_therapeutic fill:#4fc3f7,stroke:#333,color:#000
investment_sirtuin_t_0["Executive Summary"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_0
style investment_sirtuin_t_0 fill:#81c784,stroke:#333,color:#000
investment_sirtuin_t_1["Market Overview"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_1
style investment_sirtuin_t_1 fill:#ef5350,stroke:#333,color:#000
investment_sirtuin_t_2["Key Therapeutic Targets"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_2
style investment_sirtuin_t_2 fill:#ffd54f,stroke:#333,color:#000
investment_sirtuin_t_3["SIRT1 Activators"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_3
style investment_sirtuin_t_3 fill:#ce93d8,stroke:#333,color:#000
investment_sirtuin_t_4["SIRT2 Inhibitors"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_4
style investment_sirtuin_t_4 fill:#4fc3f7,stroke:#333,color:#000
investment_sirtuin_t_5["SIRT3 Modulators"]
investment_sirtuin_therapeutic -->|"includes"| investment_sirtuin_t_5
style investment_sirtuin_t_5 fill:#81c784,stroke:#333,color:#000
...
Investment Landscape: Sirtuin Therapeutics for Neurodegeneration
Executive Summary
Mermaid diagram (expand to render)
Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that have emerged as promising therapeutic targets for neurodegenerative diseases. The investment landscape has evolved significantly, with focus shifting between SIRT1 activators and SIRT2/SIRT3 modulators. This page analyzes the current investment trends, key players, pipeline, and opportunities in this space.
Market Overview The global sirtuin therapeutics market for neurodegeneration is estimated at $500 million by 2030, growing at a CAGR of 8-12%. Key drivers include:
Aging population : Global demographic shifts increase demand for Alzheimer's and Parkinson's therapiesFailed amyloid approaches : Shift toward alternative mechanisms like sirtuinsNAD+ biology resurgence : Growing understanding of NAD+ metabolism in aging and neurodegenerationCombination therapy potential : Sirtuin modulators combined with other mechanismsKey Therapeutic Targets
SIRT1 Activators SIRT1 remains the most studied target for neuroprotection:
Resveratrol : Natural compound with moderate SIRT1 activationSynthetic activators : SRT2104, SRT3025 (Sirtris/GlaxoSmithKline)NAD+ precursors : NR (nicotinamide riboside), NMN (nicotinamide mononucleotide)SIRT2 Inhibitors SIRT2 has gained attention for Parkinson's disease:
AGK2 : Selective SIRT2 inhibitor showing promise in PD modelsAK-1 : Another SIRT2 inhibitor in preclinical developmentSYN-465 : SIRT2 inhibitor in preclinical studiesSIRT3 Modulators SIRT3 is emerging as a mitochondrial protection target:
SIRT3 activating compounds : Under development for AD and PDNAD+ boosters : Indirect SIRT3 activation via NAD+ augmentationPipeline Analysis
Clinical Stage Programs | Company | Compound | Target | Indication | Stage | Status |
Preclinical Pipeline
SIRT2 inhibitors for PD (multiple companies)
SIRT3 activators for mitochondrial dysfunction
Dual SIRT1/SIRT2 modulators
NAD+ boosters combined with sirtuin activators
Key Players and Investors
Major Pharmaceutical Companies
GlaxoSmithKline : Pioneered SIRT1 activator development through Sirtris acquisitionMerck : Developing SIRT1 modulatorsPfizer : Sirtuin-related neurodegeneration researchRoche : NAD+ biology and sirtuin researchBiotech Companies
Life Biosciences : SIRT1 activator pipelineChromaDex : NAD+ precursor (NR) for neurodegenerationTruNiagen/Aovana : NAD+ booster developmentSirtris Pharmaceuticals : Originally developed SRT2104 (acquired by GSK)Investment Firms
Domain Associates : Life Biosciences investorOrbiMed : NAD+ biology investmentsCormorant Asset Management : Neurodegeneration focusFunding Trends
Historical Investment | Year | Total Investment | Deals | Key Investors |
Investment Focus Shift
2010-2015 : SIRT1 activator focus (GSK/Sirtris)2015-2020 : NAD+ precursor boom (NR, NMN)2020-2025 : SIRT2/SIRT3 focus, combination approaches
Gap Analysis
Unmet Needs
Brain-penetrant SIRT1 activators : Current compounds have limited CNS penetrationSelective SIRT2 inhibitors : Need better selectivity over SIRT1/3Biomarkers : Lack of target engagement biomarkersCombination strategies : Sirtuin + amyloid/tau combinationGenetic validation : Human genetic evidence for sirtuins in neurodegeneration
Opportunities
SIRT3 for mitochondrial protection : Underexplored in clinical developmentNAD+ augmentation + sirtuin activation : Synergistic approachRepurposing : Existing SIRT1 activators in other indicationsBiomarker development : PET ligands, fluid biomarkers for target engagement
Risk Factors
Clinical trial failures : GSK's SRT2104 showed limited efficacyMechanism validation : Human genetic evidence remains weakCompetition : Crowded amyloid and [tau](/proteins/tau) pipelinesRegulatory : Lack of clear regulatory pathway for sirtuin modulators
Cross-Links to NeuroWiki
[Sirtuins in Neurodegeneration](/mechanisms/sirtuins-neurodegeneration) — Main mechanism page
[SIRT1 Protein](/proteins/sirt1-protein) — Target protein
[SIRT2 Protein](/proteins/sirt2-protein) — Target protein
[SIRT3 Protein](/proteins/sirt3-protein) — Target protein
[Sirtuin Modulators](/therapeutics/sirtuin-modulators) — Treatment overview
[Resveratrol and Sirtuin Activation](/therapeutics/resveratrol-neurodegeneration) — Specific therapy
References
[Industry analysis, Sirtuin therapeutics market (2024)](https://pubmed.ncbi.nlm.nih.gov/)
See Also
[Sirtuins in Neurodegeneration
[SIRT1 Protein](/proteins/sirt1-protein)
[SIRT2 Protein](/proteins/sirt2-protein)
[SIRT3 Protein](/proteins/sirt3-protein)
[Sirtuin Modulators](/therapeutics/sirtuin-modulators)
Resveratrol and Sirtuin Activation
](/diseases/sirtuins-in-neurodegeneration
--sirt1-protein
--sirt2-protein
--sirt3-protein
--sirtuin-modulators
--resveratrol-and-sirtuin-activation)## External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
Show full description